Eagle Health Investments LP Makes New $2.15 Million Investment in Disc Medicine, Inc. $IRON

Eagle Health Investments LP acquired a new position in shares of Disc Medicine, Inc. (NASDAQ:IRON) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 27,100 shares of the company’s stock, valued at approximately $2,152,000. Disc Medicine accounts for 0.5% of Eagle Health Investments LP’s investment portfolio, making the stock its 28th biggest position.

Other institutional investors also recently bought and sold shares of the company. ANTIPODES PARTNERS Ltd purchased a new position in Disc Medicine during the 4th quarter worth $33,000. Aster Capital Management DIFC Ltd purchased a new position in Disc Medicine during the 3rd quarter worth $38,000. KBC Group NV purchased a new position in Disc Medicine during the 4th quarter worth $80,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Disc Medicine by 36.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,834 shares of the company’s stock worth $146,000 after purchasing an additional 490 shares during the period. Finally, Avanza Fonder AB increased its holdings in Disc Medicine by 14.1% during the 4th quarter. Avanza Fonder AB now owns 1,903 shares of the company’s stock worth $151,000 after purchasing an additional 235 shares during the period. 83.70% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Disc Medicine

In related news, insider William Jacob Savage sold 7,378 shares of the business’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $65.88, for a total transaction of $486,062.64. Following the transaction, the insider directly owned 85,211 shares in the company, valued at $5,613,700.68. The trade was a 7.97% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Jean M. Franchi sold 6,257 shares of the business’s stock in a transaction on Tuesday, April 14th. The stock was sold at an average price of $69.24, for a total value of $433,234.68. Following the transaction, the chief financial officer owned 64,333 shares in the company, valued at approximately $4,454,416.92. This trade represents a 8.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 20,119 shares of company stock worth $1,351,699. 3.76% of the stock is owned by company insiders.

Disc Medicine Stock Up 4.6%

Shares of IRON stock opened at $67.03 on Thursday. Disc Medicine, Inc. has a 1-year low of $40.00 and a 1-year high of $99.50. The stock’s fifty day moving average price is $65.66 and its 200 day moving average price is $74.75. The company has a debt-to-equity ratio of 0.04, a current ratio of 24.00 and a quick ratio of 24.00. The company has a market cap of $2.56 billion, a price-to-earnings ratio of -10.13 and a beta of 0.93.

Disc Medicine (NASDAQ:IRON) last announced its earnings results on Tuesday, May 5th. The company reported ($1.65) earnings per share for the quarter, missing the consensus estimate of ($1.62) by ($0.03). On average, research analysts expect that Disc Medicine, Inc. will post -6.78 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on IRON shares. BMO Capital Markets reduced their price objective on Disc Medicine from $120.00 to $100.00 and set an “outperform” rating on the stock in a report on Tuesday, February 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Disc Medicine in a report on Monday, April 20th. Cantor Fitzgerald reduced their price objective on Disc Medicine from $153.00 to $125.00 and set an “overweight” rating on the stock in a report on Tuesday, February 17th. Wall Street Zen upgraded Disc Medicine from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. Finally, Morgan Stanley raised their price objective on Disc Medicine from $75.00 to $80.00 and gave the stock an “overweight” rating in a report on Thursday, May 14th. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Disc Medicine has an average rating of “Moderate Buy” and a consensus target price of $105.30.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.